Skip to main content

Impact of platelet activation on the release of cell-free mitochondria and circulating mitochondrial DNA.

Roch B, Pisareva E, Mirandola A, Sanchez C, Pastor B, Tanos R, Frayssinoux F, Diab-Assaf M, Anker P, Al Amir Dache Z, Thierry AR

Publication: Clin Chim Acta (2024) • Vol 553 • Page 117711PMID: 38101467View on PubMed

Purpose

This paper investigated how the yield of cell-free mitochondrial DNA (cfmtDNA) is affected by isolating plasma using a standard protocol (SP) versus a protocol designed to reduce platelet activation (PA; protocol w/o PA) and to assess the effects of removing vesicle-associated cfmtDNA by additional steps involving filtration (0.22 µm filter) or centrifugation (16,000 x g for 10 min at 4°C) immediately or after frozen storage at -20°C. Plasma of healthy volunteers were used for the study.

Conclusion

When plasma obtained using either the SP or protocol w/o PA was subjected to an additional step involving filtration (0.22 µm) or high-speed centrifugation (16,000 x g), the cfmtDNA yield decreased significantly relative to plasma not subjected to further purification. The authors state that the decrease is due to removal of vesicles associated with cfmtDNA. Interestingly, plasma isolated by the SP that was frozen before high-speed centrifugation had 1.2-fold higher levels of cfmtDNA than plasma that underwent high-speed centrifugation directly after isolation (P=0.01), but this difference was not significant when plasma was isolated using the protocol w/o PA. The proportion by which cfmtDNA decreased following filtration or high-speed centrifugation was much greater when plasma was obtained by the SP than the protocol w/o PA (64-fold versus 5-fold and 128-fold versus 4-fold, respectively). The proportion of cfmtDNA to total cfDNA was also lower without the additional high-speed centrifugation or filtration step when plasma was obtained by the protocol w/o PA compared to when obtained by the SP (0.5% versus 19.5%). According to the authors, this supports that platelet activation is a confounding factor that must be considered when studying cfmtDNA. 

Studies (1)

Purpose

This study investigated how the yield of cell-free mitochondrial DNA (cfmtDNA) is affected by isolating plasma using a standard protocol (SP) versus a protocol designed to reduce platelet activation (PA; protocol w/o PA) and to assess the effects of removing vesicle-associated cfmtDNA by additional steps involving filtration (0.22 µm filter) or centrifugation (16,000 x g for 10 min at 4°C) immediately or after frozen storage at -20°C. Blood was collected from seven healthy volunteers (five male and two female) into EDTA vacutainer tubes and citrate-theophylline-adenosine-dipyridamole (CTAD) tubes. Plasma was obtained from EDTA blood by the standard protocol (SP), which consisted of centrifugation at 1200 x g for 10 min at 4°C. Plasma was obtained from CTAD tubes using the protocol without platelet activation (protocol w/o PA), which consisted of centrifugation twice at 200 x g for 10 min at room temperature, centrifugation at 300 x g for 10 min at room temperature, addition of prewarmed citrate dextrose buffer and prostaglandin, centrifugation at 1100 x g for 10 min at room temperature, and centrifugation at 2500 x g for 10 min at room temperature. To test the effects of removing vesicle-associated cfmtDNA by filtration and freezing, plasma aliquots obtained by the SP and the protocol w/o PA were subjected to: 1) no additional treatment, 2) filtration through a 0.22 µm filter, 3) centrifugation at 16,000 x g for 10 min at 4°C, or 4) storage at -20°C before centrifugation at 16,000 x g for 10 min at 4°C. cfDNA was extracted from plasma using the QIAamp DNA Blood Mini Kit and stored at -20°C. cfDNA was quantified and integrity evaluated by real-time PCR amplification of short and long amplicons of nuclear KRAS (67 bp and 320 bp) and mitochondrial MT-CO3 (67 bp and 310 bp) and integrity evaluated.

Summary of Findings

In plasma prepared using the SP, cfmtDNA had a ratio of long (310 bp) to short (67 bp) fragments that was close to 1 (0.96-1.07), but nuclear DNA had lower ratios of long to short fragments (0.09-0.48). When plasma obtained by the SP included a filtration (0.22 µm) or high-speed centrifugation step (16,000 x g) the cfmtDNA yield decreased by 98.7% and 99.4%, respectively (P=0.0004, both). The authors state that the decrease is due to removal of vesicle-associated cfmtDNA. Interestingly, plasma that was frozen before high-speed centrifugation had 1.2-fold higher levels of cfmtDNA than plasma that underwent high-speed centrifugation directly after plasma isolation (P=0.01), indicating that freezing releases some of the vesicle-associated cfmtDNA that was otherwise eliminated by high-speed centrifugation. In plasma obtained using the protocol w/o PA, subsequent filtration or high-speed centrifugation reduced the cfmtDNA yields by 80.04% (P=0.012) and 75.67% (P=0.010), respectively; there was no significant effect of adding a freezing step before high-speed centrifugation versus high-speed centrifugation alone. The decrease in mtDNA following filtration or high-speed centrifugation was much larger when plasma was obtained by the SP compared to the protocol w/o PA (64-fold versus 5-fold and 128-fold versus 4-fold, respectively). The proportion of cfmtDNA to total cfDNA was also lower in specimens that were processed without a high-speed centrifugation or filtration step when processed using the protocol w/o PA than when the SP was used (0.5% versus 19.5%). According to the authors, this supports that platelet activation is a confounding factor that must be considered when studying cfmtDNA. 

  • Biospecimens

    FluidBlood
    FluidPlasma
  • Preservation Types

    FrozenNone (Fresh)
  • Diagnoses

    Normal
  • Platforms

    DNAReal-time qPCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionAnticoagulant
    Citrate-theophylline-adenosine-dipyridamole
    EDTA
    Biospecimen Aliquots and ComponentsBlood processing method
    Standard protocol (EDTA blood centrifuged at 1200g for 10 min)
    Without platelet activation (CTAD blood centrifuged twice at 200g for 10 min, 300 g for 10 min, mixed with ACD and prostaglandin, centrifuged at 1100g for 10 min, centrifuged at 2500 x g for 10 min)
    Biospecimen Aliquots and ComponentsCentrifugation
    Centrifugation delays investigated
    Different number of centrifugation steps compared
    Multiple speeds compared
    Biospecimen Aliquots and ComponentsFiltration
    Not filtered
    Plasma filtered through 0.22 µm filter